Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.
Lee CK, Davies L, Gebski VJ, Lord SJ, Di Leo A, Johnston S, Geyer C Jr, Cameron D, Press MF, Ellis C, Loi S, Marschner I, Simes J, de Souza P.
Lee CK, et al.
J Clin Oncol. 2016 Mar 20;34(9):936-44. doi: 10.1200/JCO.2015.62.4767. Epub 2016 Jan 25.
J Clin Oncol. 2016.
PMID: 26811533
RESULTS: Median sHER2 levels were 25.1 and 10.1 ng/mL in tHER2-amplified (tHER-positive) and nonamplified (tHER-negative) populations, respectively (r = 0.42 for sHER2-tHER2 correlation). Lapatinib had significant PFS benefit over control (hazard ratio [HR], 0.855; P = .00 …
RESULTS: Median sHER2 levels were 25.1 and 10.1 ng/mL in tHER2-amplified (tHER-positive) and nonamplified (tHER-negative) populations, respe …